B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity
TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 price target.
Macrogenics Inc (MGNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Walleye Capital Will England | 408,150 | $1,885,653 | +22% | 0.01% |
| 2. | Persistent Asset Partners Xin Huang | 95,371 | $440,614 | -38% | 0.13% |
| 3. | NVerses Capital Jb Kim | 29,090 | $134,395 | 0.21% | |
| 4. | 2,400 | $11,088 | -97% | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.49 | 49,500 | $73,755.00 | 111,000 | 2025-08-20 | Filing | |
| $1.52 | 50,500 | $76,760.00 | 61,500 | 2025-08-19 | Filing | |
| $4.46 | 150,000 | $669,585.00 | 9,929,963 | 2023-10-02 | Filing | |
| $5.26 | 200,000 | $1,052,840.00 | 9,779,963 | 2023-09-07 | Filing | |
| $4.91 | 15,000 | $73,650.00 | 33,074 | 2023-08-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.56 | 423 | $1,082.88 | 9,532 | 2025-02-15 | Filing | |
| $18.22 | 3,165 | $57,666.30 | 0 | 2024-04-04 | Filing | |
| $17.74 | 5,351 | $94,926.74 | 3,165 | 2024-04-04 | Filing | |
| $16.38 | 232 | $3,800.16 | 8,516 | 2024-04-04 | Filing | |
| $15.51 | 147 | $2,279.97 | 8,748 | 2024-04-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,679,229 | $21,618,040 | 0% | |
| 2. | 2,018,881 | $9,327,230 | 0.06% | |
| 3. | 863,663 | $3,990,123 | 0% | |
| 4. | 254,301 | $1,174,871 | 0.01% | |
| 5. | 250,154 | $1,155,711 | 0% |
News See All
10 Best Biotech Stocks Under $10 to Buy
According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years.
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics Fourth Quarter and Full Year 2024 Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2024 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2024 First Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 Fourth Quarter Corporate Progress and Financial Results Conference Call in just a moment.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
MacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 Second Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 First Quarter Corporate Progress and Financial Results Conference Call in just a moment.
Hedge Fund Resource Center